Progyny (PGNY) Crashes After Losing Significant Client - Hagens Berman
SAN FRANCISCO, Sept. 19, 2024 (GLOBE NEWSWIRE) -- Hagens Berman urges Progyny, Inc. (NASDAQ: PGNY) investors who suffered substantial losses to submit your losses now. The firm also encourages pers...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Progyny, Inc. - PGNY
NEW YORK, NY / ACCESSWIRE / September 19, 2024 / Pomerantz LLP is investigating claims on behalf of investors of Progyny, Inc. ("Progyny" or the "Company") (NASDAQ:PGNY). Such investors are advised...
Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Progyny, Inc. (PGNY) And Encourages Stockholders to Reach Out
NEW YORK CITY, NY / ACCESSWIRE / September 19, 2024 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Progyny, Inc. ("Progyny" or "the Company") (NAS...
Fertility-benefits provider Progyny's stock on track for biggest-ever decline after losing ‘significant' client
Progyny Inc.'s stock tumbled 31% Thursday, to put it on track for its biggest-ever one-day decline, after the provider of fertility-care benefits for employers said a “significant” client had termi...
Progyny: Downgrading As Uncertainties Increase
Progyny lowered full-year revenue guidance after seeing an unexpected drop in user utilization rates. The Harris-Walz ticket has put fertility benefits center stage in the upcoming presidential ele...
Progyny (PGNY) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates
Although the revenue and EPS for Progyny (PGNY) give a sense of how its business performed in the quarter ended June 2024, it might be worth considering how some key metrics compare with Wall Stree...
Progyny (PGNY) Beats Q2 Earnings Estimates
Progyny (PGNY) came out with quarterly earnings of $0.43 per share, beating the Zacks Consensus Estimate of $0.36 per share. This compares to earnings of $0.15 per share a year ago.
Assisted Reproductive Technology Market Report 2024-2033: Vitrolife Leads the Competition with 9.8% Share, Followed by Ferring, and Progyny
Dublin, July 12, 2024 (GLOBE NEWSWIRE) -- The "Assisted Reproductive Technology Global Market Opportunities and Strategies to 2033" report has been added to ResearchAndMarkets.com's offering. The g...
Progyny, Inc. to Host 2024 Inaugural Investor Day
NEW YORK, June 26, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that it will host its in...
Progyny: No Change To Long-Term Outlook
PGNY experienced a revenue miss in 1Q24 due to weak utilization. Historical data shows that IVF demand has been resilient, with strong rebounds following economic downturns. Leading indicators sugg...
Progyny's board approves another $100 million stock buyback
The board of Progyny PGNY, -2.62% has approved a $100 million share-repurchase authorization, its second this year.
Progyny's stock plunges as demand for IVF treatments drops after Alabama ruling
Shares of Progyny Inc. were headed for a record selloff Friday after the fertility-services company said the Supreme Court of Alabama's February ruling regarding in vitro fertilization seemed to sc...
Progyny, Inc. (PGNY) Q1 2024 Earnings Call Transcript
Progyny, Inc. (NASDAQ:PGNY ) Q1 2024 Earnings Conference Call May 9, 2024 4:45 PM ET Company Participants James Hart – Investor Relations Pete Anevski – Chief Executive Officer Mark Livingston – Ch...
Progyny: Long-Term Outlook Remains Positive, Reiterate Buy
Progyny, Inc. (PGNY) is recommended as a buy due to its potential for continued growth and positive long-term outlook. The recent weak share price is attributed to expected weak performance in 1Q24...
Progyny, Inc. to Present at Barclays 26th Annual Global Healthcare Conference
NEW YORK, March 11, 2024 (GLOBE NEWSWIRE) -- Progyny, Inc. (Nasdaq: PGNY), a transformative fertility, family building, and women's health benefits solution, today announced that Pete Anevski, Prog...
Related Companies